Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation

References

• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693.
   PubMed Web of Science ®Google Scholar
• Yao F, Ferrell L, Bass N, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.
   PubMed Web of Science ®Google Scholar
• Söderdahl G, Sternby Eilard M, Rizell M. [Selection criteria decisive in hepatocellular carcinoma]. Lakartidningen. 2012;109:1750–1753.
   PubMedGoogle Scholar
• Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524–532.
   PubMed Web of Science ®Google Scholar
• Zhang N, Gu J, Yin L, et al. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget. 2016;7:81389–81401.
   PubMedGoogle Scholar
• Yang SL, Liu LP, Yang S, et al. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103:716–724.
   PubMed Web of Science ®Google Scholar
• Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19:634–645.
   PubMed Web of Science ®Google Scholar
• Lai Q, Iesari S, Melandro F, et al. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol. 2017;2:72.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cho Y, Kim HY, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016;263:842–850.
   PubMed Web of Science ®Google Scholar
• Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci. 2015;22:279–286.
   PubMed Web of Science ®Google Scholar
• Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: hangzhou experiences. Transplantation. 2008;85:1726–1732.
   PubMed Web of Science ®Google Scholar
• Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. Eur J Gastroenterol Hepatol. 2014;26:200–204.
   PubMed Web of Science ®Google Scholar
• Grąt M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and alpha-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–2707.
   PubMed Web of Science ®Google Scholar
• Hameed B, Mehta N, Sapisochin G, et al. Alpha-fetoprotein level >1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945–951.
   PubMed Web of Science ®Google Scholar
• Söderdahl G, Bäckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transplant Int. 2006;19:288–294.
   PubMed Web of Science ®Google Scholar
• StataCorp. Statistical software. College Station, TX: StataCorp LLC; 2017.
   Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18: 695–706.
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MKB. Flexible proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statist Med. 2002;21:2175–2197.
   PubMed Web of Science ®Google Scholar
• Royston P, Lambert PC. Flexible parametric survival analysis using stata [Elektronic resource]: beyond the Cox model. College Station, TX: StataCorp.; 2011.
   Google Scholar
• Chen CL, Concejero AM. Liver transplantation for hepatocellular carcinoma in the world: the Taiwan experience. J Hepatobiliary Pancreat Sci. 2010;17:555–558.
   PubMed Web of Science ®Google Scholar
• Ciccarelli O, Lai Q, Goffette P, et al. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int. 2012;25:867–875.
   PubMed Web of Science ®Google Scholar
• Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:599–606.
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994.e3; quiz e14-5.
   PubMed Web of Science ®Google Scholar
• The MetroTicket Calculator. The Metroticket Project; 2016. Available from: http://www.hcc-olt-metroticket.org/#project
   Google Scholar
• Hakeem AR, Young RS, Marangoni G, et al. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:987–999.
   PubMed Web of Science ®Google Scholar
• Merani S, Majno P, Kneteman N, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–819.
   PubMed Web of Science ®Google Scholar
• Lai Q, Inostroza M, Rico Juri JM, et al. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford). 2015;17:1085–1095.
   PubMed Web of Science ®Google Scholar
• Giard J-M, Mehta N, Dodge JL, et al. Alpha-fetoprotein slope >7.5 ng/ml per month predicts microvascular invasion and tumor recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2018;102:816–822.
   PubMed Web of Science ®Google Scholar
• Graąt M, Krasnodeębski M, Patkowski W, et al. Relevance of pre-transplant a-fetoprotein dynamics in liver transplantation for hepatocellular cancer. Ann Transplant. 2016;21:115–124.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Shimamura T, Suzuki T, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Sci. 2010;17:533–538.
   PubMed Web of Science ®Google Scholar
• Lai Q, Levi SGB, Lerut J. Selection tool alpha-fetoprotein for patients waiting for liver transplantation: how to easily manage a fractal algorithm. World J Hepatol. 2015;7:1899–1904.
   PubMed Web of Science ®Google Scholar
• Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci. 2010;17:527–532.
   PubMed Web of Science ®Google Scholar
• Toso C, Kneteman N, Shapiro J, et al. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Eur Soc Organ Transpl. 2009;22:869–875.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154:128–139.
   PubMed Web of Science ®Google Scholar
• Grat M, Wronka KM, Stypułkowski J, et al. The Warsaw proposal for the use of extended selection criteria in liver transplantation for hepatocellular cancer. Ann Surg Oncol. 2017;24:526–534.
   PubMed Web of Science ®Google Scholar
• Pinero F, Tisi Baña M, Cristinade Ataide E, et al. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int. 2016;36:1657–1667.
   PubMed Web of Science ®Google Scholar
• Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552–559.
   PubMed Web of Science ®Google Scholar
• Melum E, editor. The Nordic Liver Transplant Registry (NTLR): annual report 2016 [Internet]. Aarhus: Scandiatransplant; 2016 [cited 2018 May 15]. Available from: http://www.scandiatransplant.org/members/nltr/TheNordicLiverTransplantRegistryANNUALREPORT2015.pdf
   Google Scholar
• Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79–88.
   PubMed Web of Science ®Google Scholar